|Bid||8.55 x 900|
|Ask||8.70 x 800|
|Day's Range||7.86 - 9.23|
|52 Week Range||4.96 - 9.23|
|Beta (5Y Monthly)||1.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.86|
Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.
The company's Japanese partner initiated pivotal late-stage studies of Ardelyx's lead candidate.
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that its collaboration partner in Japan, Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), has initiated four Phase 3 clinical studies in Japan evaluating tenapanor for hyperphosphatemia. The achievement of this development milestone triggers a $5 million payment to Ardelyx.